For example, the combination of Olaratumab, a monoclonal antibody against platelet-derived growth factor receptor alpha, with doxorubicin provided no detectable clinical benefit in terms of PFS and overall survival in osteosarcoma compared to conventional chemotherapy [60]. Here, PDGFRA is linked to osteosarcoma.